Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ariad shares soar 34% on positive Phase III outcome data for mTOR inhibitor in sarcoma

This article was originally published in Scrip

Executive Summary

Ariad Pharmaceuticals' shares jumped after it reported positive top-line results from a Phase III trial of its investigational mTOR inhibitor, ridaforolimus – specifically a 28% reduction in the risk of progression in sarcoma compared to the placebo group, and a 21% (or 3.1 week) improvement in progression-free survival, as determined by an independent panel, achieving the primary endpoint of the study. The shares soared $1.78, or 34%, to close at $7.04,$226 million adding to the company's value for a 18 January closing market capitalisation of $666 million.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC011529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel